"India halts production of cough syrups suspected of links to child deaths" 14 October

Indian health authorities have halted production at a pharmaceutical company in New Delhi after the World Health Organization (WHO) said its cough and cold syrups may be linked to the deaths of dozens of children.

The WHO suspects that four of the syrups made by Maiden Pharmaceuticals Limited – Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup – have “unacceptable amounts” of chemicals that can damage the brain, lungs, liver and kidneys of those who take them.

Health officials believe the medicines may be linked to the deaths of more than 60 children in the Gambia, Africa, and potentially more than 20 children in the Southeast Asian country of Indonesia.

On Wednesday, India’s Central Drugs Standard Control Organization said Maiden Pharmaceuticals had been “manufacturing and testing drugs without adhering to, and in contravention of, the various good manufacturing practice requirements.”

“In view of the seriousness of the contraventions observed during the investigation and its potential risk to the quality, safety and efficacy of the drugs being produced, all the manufacturing activities of the firm (are) being stopped with immediate effect,” it said.

The WHO has previously issued an alert regarding the medicines and they have been recalled by the Gambian Medicine Control Agency.

The alarm was first raised by medical officers in the Gambia, after an unusual number of children began dying from kidney problems. The deaths confounded medics until a pattern emerged: dozens of patients younger than five had fallen ill three to five days after taking a locally sold syrup made by Maiden Pharmaceuticals.

A subsequent analysis by the WHO of the four syrups made by Maiden found them to contain “unacceptable amounts” ​of diethylene glycol and ethylene glycol, which can damage the brain, lungs, liver and kidneys.

...

CNN has reached out to Maiden Pharmaceuticals Limited, but has not yet heard back.

However, the company has previously published links to the WHO’s medical product alert and the Gambian Medicine Control Agency’s recall notice.